Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41591-021-01639-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Retracted] Tan IIA inhibits H1299 cell viability through the MDM4‑IAP3 signaling pathway.
Mol Med Rep
March 2025
Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Following the publication of the above paper, it was drawn to the Editors' attention by a concerned reader that certain of the western blotting data shown in Fig. 1C and D on p. 2386 were strikingly similar to data appearing in different form in a pair of other articles written by different authors at a different research institute that had already been published elsewhere prior to the submission of this paper to .
View Article and Find Full Text PDFReply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation.
J Clin Oncol
January 2025
George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; and Jeffrey A. Gilreath, PharmD, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, Department of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation.
J Clin Oncol
January 2025
Shun Lu, MD, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; and Jiong Wu, MD, Cancer Hospital, Fudan University, Shanghai, China.
Reply to: Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Addressing Statistical and Methodological Concerns in Survival Analysis.
J Clin Oncol
January 2025
Joseph R. Habib, MD, Ammar A. Javed, MD, and Christopher L. Wolfgang, MD, PhD, New York University Grossman School of Medicine, New York, NY.
Stereotactic body radiotherapy and poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a knowledge and attitudes survey in collaboration with the Italian Association of Radiation Oncology (AIRO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups.
Anticancer Drugs
January 2025
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica.
The aim of this study was to present a nationwide survey on the specialist's attitudes towards stereotactic body radiotherapy (SBRT) combined with poly (ADP-ribose) polymerase inhibitors (PARPi) with oligometastatic/oligoprogressive/oligorecurrent ovarian cancer (oMPR-OC) patients. The 19-item questionnaire was developed by specialists and distributed online. Replies were stratified by categories and analyzed using descriptive statistics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!